Similar Papers

Paper Title
Journal
Date
Author
One-Year Outcomes of 1 Dose versus 3 Loading Doses Followed by Pro Re Nata Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration: The ARTIS Trial.
Fenghua Wang ... Jingke Zhao
Journal of Ophthalmology | VOL. 2019
Fenghua Wang, et. al.Fenghua Wang ... Jingke Zhao
10 Oct 2019
Treat and Extend versus Pro Re Nata regimens of ranibizumab in neovascular age-related macular degeneration: a comparative 12 Month study.
Katja Hatz ... Christian Prünte
Acta Ophthalmologica | VOL. 95
Katja Hatz, et. al.Katja Hatz ... Christian Prünte
24 Mar 2016
One-Year Outcomes of 1 + pro re nata versus 3 + pro re nata Intravitreal Aflibercept Injection for Neovascular Age-Related Macular Degeneration
Kei Takayama ... Tadasu Sugita
Ophthalmologica | VOL. 237
Kei Takayama, et. al.Kei Takayama ... Tadasu Sugita
24 Feb 2017
Different conbercept injection strategies for the treatment of exudative age-related macular degeneration: A retrospective cohort study.
Lei Gao ... Hong Wang
Medicine | VOL. 99
Lei Gao, et. al.Lei Gao ... Hong Wang
01 Feb 2020
View more papers

More From: British Journal of Ophthalmology

Paper Title
Journal
Date
Author
High-sensitivity C-reactive protein and risk of retinal artery occlusion and ischaemic stroke: a cross-cohort study
Yaxin Wang ... Xiangjun Chen
British Journal of Ophthalmology | VOL. -
Yaxin Wang, et. al.Yaxin Wang ... Xiangjun Chen
04 Feb 2025
Evaluating lipid-lowering drug targets for full-course diabetic retinopathy
Jiahui Cao ... Honghua Yu
British Journal of Ophthalmology | VOL. -
Jiahui Cao, et. al.Jiahui Cao ... Honghua Yu
03 Feb 2025
Risk factors for rapid axial length growth in a prospective cohort study of 3-year to 9-year-old Chinese children
Yanze Yu ... Jing Zhao
British Journal of Ophthalmology | VOL. -
Yanze Yu, et. al.Yanze Yu ... Jing Zhao
31 Jan 2025
Registry-based randomised controlled trials in glaucoma: the time is right?
Mitchell Lawlor ... Gus Gazzard
British Journal of Ophthalmology | VOL. -
Mitchell Lawlor, et. al.Mitchell Lawlor ... Gus Gazzard
30 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.